OncRef

Clinical Trial: NCT00939770

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Children's Oncology Group
Information Provided By:Children's Oncology Group
Last Update Posted:2020-06-09

Study Overview

Brief Summary

This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)

Official Title

A Phase 1/2 Study of Crizotinib, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

Conditions

Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma

Intervention / Treatment

  • Drug: Crizotinib
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Other: Questionnaire Administration

Other Study ID Numbers

  • ADVL0912
  • NCI-2011-01937
  • P10666
  • COG-ADVL0912
  • CDR0000647587
  • ADVL0912
  • ADVL0912
  • UM1CA097452

Start Date (Actual)

2009-09-21

Primary Completion Date (Actual)

2018-12-31

Study Completion Date (Actual)

2018-12-31

Enrollment (Actual)

122

Study Type

Interventional

Phase

Phase 1, Phase 2